Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

Fig. 3

Change from baseline in proportion of patients per level of perceived problems in EQ-5D dimensions. a) Usual activities; b) pain/discomfort; c) anxiety/depression; d) mobility; and e) self-care. All dimensions evaluated at administration visit 1 through visit 8.* EQ-5D = EuroQol 5-Dimension Questionnaire. *The numbers of patients in administration (Admin) visits 9–13 in all dimensions were as follows: Admin 9, n = 119; Admin 10, n = 50; Admin 11, n = 24; Admin 12, n = 13; Admin 13, n = 7

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us